Huesca

The study focuses on patients with splenomegaly or those who have undergone splenectomy without a clear diagnosis, as well as patients with thrombocytopenia. Researchers aim to improve diagnosis sensitivity for Gaucher disease (GD) and Acid Sphingomyelinase Deficiency (ASMD) among these patients, especially in those with monoclonal gammopathies of undetermined significance (MGUS) or multiple myeloma (MM). Previous research suggests increased frequency of MGUS and MM in GD and ASMD patients, but many cases of splenomegaly remain unexplained despite standard evaluations. The study involves the use of usual clinical diagnostic procedures alongside collecting blood samples for a dry drop test (DBS) to measure enzymatic and genetic activity related to GD and ASMD. Analysis of specific markers LisoGl1 and LisoSM will also be conducted. The investigation seeks to identify the prevalence of these diseases in the patient population over a 36-month period. Participants will undergo clinical evaluation, blood testing, and enzymatic/genetic assessments to help identify GD and ASMD. Researchers will monitor the prevalence of these diseases and related conditions throughout the study. The study includes adult patients aged 18 to 99 years, and those who participate will provide consent for assessments and follow-up. Safety and diagnostic results will be observed during the entire study duration.

This research aims to evaluate a motivational training program designed for pre-service Physical Education teachers. The study focuses on how different teaching styles influence motivation and competence in teaching, using frameworks like Self-Determination Theory and the circumplex model. It addresses the need for training programs that encourage motivating teaching approaches while reducing demotivating ones during initial teacher education. The study involves at least 38 pre-service teachers enrolled in a Master's program in Physical Education Teacher Education at the University of Zaragoza. Participants are divided into an experimental group, which receives a 14-hour training program combining theoretical and practical sessions based on motivational theories, and a control group that follows the standard curriculum without this specific intervention. Participants will complete questionnaires measuring motivating and demotivating teaching styles, teaching competence, and motivation to teach at baseline, 4 weeks, and 8 months after baseline. The experimental group must attend all training sessions and participate in a final focus group discussion. Independent researchers will conduct assessments, and external experts will lead focus groups to explore participants' experiences and program applicability.

Inflammatory bowel disease (IBD), including ulcerative colitis (UC) and Crohn's disease (CD), involves chronic inflammation in different parts of the digestive tract, causing relapsing symptoms. The inflammatory process features increased activated granulocytes and monocyte-macrophages, which contribute to tissue damage. Granulocytapheresis (GMA) is being studied as a treatment alternative, especially for patients dependent on corticosteroids, to reduce inflammation by selectively removing these inflammatory cells from the blood. The study evaluates the use of the Adacolumn4 medical device for GMA therapy in adults diagnosed with UC or CD under real-world conditions. Patients will receive GMA sessions typically once a week for five weeks, with some receiving more frequent or maintenance sessions depending on their condition. The treatment aims to decrease the need for steroids and may be combined with other therapies. The study includes up to four visits: baseline, 1 month, 6 months, and 12 months after the final induction session. Participants will be monitored through routine clinical visits without extra interventions beyond usual care. Data collected include clinical remission rates without steroids six months after GMA therapy, safety information, changes in treatment, and quality of life measures. The total follow-up after treatment completion is approximately 12 months, ensuring careful observation of treatment effects and patient well-being.

Researchers are conducting an observational study called SOGUG-PRINCIS to collect and analyze data on the effectiveness of drugs recently approved for treating genitourinary tumors under routine clinical practice in Spain. This national, multicenter study includes both retrospective patient data and prospective follow-up, aiming to validate real-world outcomes compared to those reported in phase III clinical trials. The study covers cancers originating in the kidney, ureter, bladder, prostate, testicle, urethra, penis, and seminal vesicles. The study observes patients treated with drugs such as darolutamide combined with androgen deprivation therapy and docetaxel, adjuvant nivolumab after surgical removal of urothelial carcinoma, and enfortumab vedotin. All treatments follow their approved dosing and administration guidelines in standard clinical practice. New subprojects may be added as new drugs gain funding approval by the Spanish National Health System, with each subproject focusing on specific primary endpoints. Participants' involvement includes treatment decisions made independently from the study, with data collected afterward to assess outcomes. Researchers will track progression-free survival at 18 months, relapse-free survival at 24 months, and overall survival at 12 months after treatment initiation. The study also serves as a registry for genitourinary cancer treatments funded nationally, supporting long-term evaluation of drug effectiveness in real-world settings.

Researchers are evaluating the safety of medications used to treat inflammatory bowel diseases (IBD), including Crohn's disease and ulcerative colitis, in pregnant women and their children. This observational registry study in Spain will follow pregnant women with IBD over five years and track their children for four years to assess the risk of serious infections, developmental issues, and other serious adverse events. The study aims to clarify the impact of these medications on pregnancy outcomes and child health, especially focusing on serious infections in children, a topic with previously conflicting results. Pregnant women with IBD will be enrolled before the 28th week of gestation and grouped based on their exposure to biologic drugs, immunomodulators, or neither during pregnancy and the three months before conception. Researchers will collect detailed information at multiple points during pregnancy and up to four years after birth. Mothers will be contacted regularly to update data on disease activity, treatment, and any serious adverse events. Children will undergo developmental assessments using questionnaires completed by their mothers at specified intervals throughout the follow-up period. Participants will have scheduled visits at baseline, each trimester, one month after delivery, and quarterly during the child's first four years. Data collected include clinical status of the mother, pregnancy complications, birth details, child development, vaccinations, infections, hospitalizations, and serious adverse events. The study will monitor outcomes such as serious infections and adverse events in both mothers and children, with data securely managed using a web-based electronic system. This long-term follow-up aims to provide comprehensive safety information on IBD treatments during pregnancy and breastfeeding.